Trobix Bio’s aim is to develop products that enhance or decrease the immune system local activity and drive local production of gut hormones, offering patients highly efficacious and safe treatments for cancer, inflammatory, and metabolic diseases with meaningful improvement of patients’ therapeutic outcomes and quality of life.

  • TBX 201

    TBX201 is designed to reduce the incidence and severity of severe diarrhea caused by irinotecan. Irinotecan is a first-line chemotherapy drug for the treatment of several metastatic cancer indications. Clinical use of irinotecan in over 100,000 patients annually is associated with life-threatening toxicity and treatment interruptions for many patients.

  • TBX 301

    TBX301 is designed to prevent the incidence and severity of colitis in patients receiving immune checkpoint inhibitors (ICI). The number of patients receiving treatment with ICI, such as CLTA-4, PD1 or PDL1 inhibitors, is rapidly increasing, with currently over 1 million patients globally treated annually with ICI. Severe life-threatening and treatment-limiting colitis is one of the lead adverse reactions to ICI treatment.

  • TBX 401

    TBX401 designed to promote weight loss, as overweight affects over 2.5 billion people worldwide, a condition leading to increased type 2 diabetes, heart disease, and risk for cancer. Recently approved treatments for obesity, led by Wegovy (GLP-1), have gained significant market with expected sales of over $100B by 2030. Nevertheless, over 70% of Wegovy treated patients do not reach target BMI and ~60% of patients dropping out of Wegovy treatment within 12 months, creating a real need for next gen obesity drugs. Different gut hormones drive multiple pathways affecting weight loss management, and TBX401 is designed to contain a combination of gut hormones to drive weight loss management efficacy. In vivo production of a combination of gut hormones, alongside continuous secretion in the gut of the combination hormones and an expected once a month pill, create attractive business drivers for TBX401, translating to a peak sales potential of $18 billion.

  • TBX 501

    TBX501 is designed to treat local and regional stage rectal cancer. Functional disturbances constitute a major problem for many surviving rectal cancer patients. Surgery results in severe loss in quality of life and has high recurrence rates, while current protocols for chemoradiotherapy result in complete clinical response in only 30% of cases. TBX501 is designed to drive In vivo production of IL-2, and the company anticipates that continuous secretion of IL-2 in the gut for local treatment, in combination with existing chemoradiotherapy, is expected to increase immune response, increase the probability for complete clinical response, and reduce the need for surgery in many cases. with over 130,000 newly annually diagnosed cases worldwide, TBX501 represents a peak sales potential of over $1 billion.